Form S-3 PERNIX THERAPEUTICS HOLD
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pernix Therapeutics (PTX) Posts Q3 Loss of 2c/Share
November 10, 2014 8:28 AM ESTPernix Therapeutics (NASDAQ: PTX) reported Q3 EPS of ($0.02), $0.02 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $31.5 million versus the consensus estimate of $28.1 million.
Pernix Therapeutics reaffirmed FY2014 guidance.
For earnings history and earnings-related data on Pernix Therapeutics (PTX) click here.
... MorePernix Therapeutics (PTX) Files $300M Mixed Shelf
November 10, 2014 8:27 AM ESTPernix Therapeutics (NASDAQ: PTX) filed with the U.S. SEC to sell up to $300 million of mixed securities.
... More